seladelpar lysine · Gilead Sciences Inc · NDA 217899
Livdelzi
Earliest generic entry, as listed
13 Mar 2038
Blocked by patent: US 10272058. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10272058 | use U-1854 | 13 Mar 2038 |
| US 11406611 | use U-1854 | 19 Mar 2035 |
| US 11596614 | use U-1854 | 19 Mar 2035 |
| US 9486428 | use U-1854 | 19 Mar 2035 |
| US 7709682 | substance | 13 Sep 2027 |
| US 7301050 | substance, product | 2 Aug 2027 |
Exclusivities · 2 unexpired
| ODE-486 | orphan drug (7 years) | 14 Aug 2031 |
| NCE | new chemical entity (5 years) | 14 Aug 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217899 · 001 · RLD | capsule, oral | EQ 10MG BASE | 13 Mar 2038 |